Antiviral activity of the plant extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii against influenza virus A/PR/8/34

Journal of Microbiology and Biotechnology

Volumn 23, Issue 1, 2013, Pages 125-130

  Won, Ji Na ^a,b   Lee, Seo Yong ^a   Song, Dae Sub ^a,b   Poo, Haryoung ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

Antiviral activity; Cytopathic effect; Influenza A virus; Plant extract

Indexed keywords

ANTIVIRUS AGENT; ASTER SPATHULIFOLIUS EXTRACT; OSELTAMIVIR; PINUS THUNBERGII EXTRACT; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; THUJA ORIENTALIS EXTRACT; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; ASTER SPATHULIFOLIUS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG MECHANISM; IN VITRO STUDY; INFLUENZA VIRUS A; MEDICINAL PLANT; NONHUMAN; PINE; PINUS THUNBERGII; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THUJA; THUJA ORIENTALIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ASTERACEAE; CELL LINE; CELL SURVIVAL; CYTOPATHOGENIC EFFECT, VIRAL; DOGS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICROBIAL SENSITIVITY TESTS; PINUS; PLANT EXTRACTS; THUJA;

EID: 84873635909     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1210.10074     Document Type: Article

References (25)

1. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
2. Cassetti, M. C., R. Couch, J. Wood, and Y. Pervikov. 2005. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 23: 1529-1533.
3. CDC. 2009. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1)-United States, May-June 2009. Morb. Mortal. Wkly. Rep. 58.
4. Choi, H. J., J. H. Song, K. S. Park, and D. H. Kwon. 2009. Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication. Eur. J. Pharm. Sci. 37: 329-333.
5. Chomczynski, P. and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159.
6. Condit, R. C. 2006. Fields virology, pp. 25-57. In D. M. Knipe and P. M. Howley (eds.). Principles of Virology, 5th Ed. Lippincott Williams and Wilkins, Philadelphia.
7. Couch, R. B. and G. G. Jackson. 1976. Antiviral agents in influenza-summary of Influenza Workshop VIII. J. Infect. Dis. 134: 516-527.
8. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30: 115-133.
9. Furuta, Y., K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, et al. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49: 981-986.
10. Garten, R. J., C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
11. Glezen, W. P. 1996. Emerging infections: Pandemic influenza. Epidemiol. Rev. 18: 64-76.
12. Hampson, A. W. 2002. Influenza virus antigens and 'antigenic drift', pp. 49-85. In C. W. Potter (ed.). Perspectives in Medical Virology, Vol. 7. Elsevier.
13. Hui, E. K. and D. P. Nayak. 2001. Role of ATP in influenza virus budding. Virology 290: 329-341.
14. Irvine, J. D., L. Takahashi, K. Lockhart, J. Cheong, J. W. Tolan, H. E. Selick, and J. R. Grove. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 88: 28-33.
15. Jackson, D. C. and L. E. Brown. 1991. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen. Pept. Res. 4: 114-124.
16. Kawaoka, Y. 2006. Influenza Virology: Current Topics. Caister Academic Press.
17. Kelly, H. and K. Grant. 2009. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: Surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro. Surveill. 14.
18. Kiso, M., K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, Q. M. Le, et al. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. USA 107: 882-887.
19. Murris-Espin, M., A. Didier, S. Mezghani, L. Lacassagne, and P. Leophonte. 1999. Influenza and asthma. Rev. Mal. Res. 16: 9-15.
20. Noah, J. W., W. Severson, D. L. Noah, L. Rasmussen, E. L. White, and C. B. Jonsson. 2007. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 73: 50-59.
21. Numazaki, Y., T. Oshima, A. Ohmi, A. Tanaka, Y. Oizumi, S. Komatsu, et al. 1987. A microplate method for isolation of viruses from infants and children with acute respiratory infections. Microbiol. Immunol. 31: 1085-1095.
22. Palese, S. M. 2007. Orthomyxoviridae: The viruses and their replication, pp. 1647-1689. In K. DM and H. PM (eds.). Fields Virology, 5th Ed. Lippincott Williams &Wilkins, Philadelphia.
23. Poland, G. A., R. M. Jacobson, and P. V. Targonski. 2007. Avian and pandemic influenza: An overview. Vaccine 25: 3057-3061.
24. Renaud, C., J. Kuypers, and J. A. Englund. 2011. Emerging oseltamivir resistance in seasonal and pandemic influenza A/ H1N1. J. Clin. Virol. 52: 70-78.
25. WHO. 2009. Summary report of a high-level consultation: New influenza A (H1N1). World Health Organization, Geneva.